Dr. Powell Discusses the Next Steps for CPI-613

Bayard L. Powell, MD
Published: Thursday, Jul 25, 2013

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.

Following a phase I trial, researchers plan to move forward with CPI-613, focusing on myelodysplastic syndrome. In the study, 3/3 patients with very refractory disease responded to treatment, which is encouraging, Powell says, though represents just a hint of activity.

CPI-613 will also be analyzed in acute myeloid leukemia, where activity was seen, in combination with high-dose cytarabine. Cytarabine is an effective treatment for patients with relapsed/refractory disease and the combination will be evaluated for tolerance and efficacy.

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.

Following a phase I trial, researchers plan to move forward with CPI-613, focusing on myelodysplastic syndrome. In the study, 3/3 patients with very refractory disease responded to treatment, which is encouraging, Powell says, though represents just a hint of activity.

CPI-613 will also be analyzed in acute myeloid leukemia, where activity was seen, in combination with high-dose cytarabine. Cytarabine is an effective treatment for patients with relapsed/refractory disease and the combination will be evaluated for tolerance and efficacy.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell TumorsApr 28, 20181.0
Publication Bottom Border
Border Publication
x